Traders Purchase High Volume of Alphatec Call Options (NASDAQ:ATEC)

Alphatec Holdings, Inc. (NASDAQ:ATEC) was the recipient of some unusual options trading activity on Friday. Stock traders bought 2,902 call options on the company. This represents an increase of 92% compared to the average volume of 1,511 call options.

Alphatec Trading Up 2.0 %

Shares of ATEC traded up $0.19 during mid-day trading on Friday, reaching $9.46. 466,159 shares of the company were exchanged, compared to its average volume of 1,975,557. The business has a 50 day simple moving average of $10.95 and a two-hundred day simple moving average of $8.70. Alphatec has a 52 week low of $4.88 and a 52 week high of $14.88. The stock has a market capitalization of $1.36 billion, a PE ratio of -7.38 and a beta of 1.39. The company has a debt-to-equity ratio of 30.21, a quick ratio of 1.15 and a current ratio of 2.32.

Alphatec (NASDAQ:ATEC) last issued its quarterly earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm had revenue of $176.79 million during the quarter, compared to analyst estimates of $172.74 million. On average, analysts predict that Alphatec will post -1.08 earnings per share for the current fiscal year.

Insider Buying and Selling at Alphatec

In other Alphatec news, COO Scott Lish sold 23,183 shares of the business’s stock in a transaction dated Thursday, February 27th. The shares were sold at an average price of $12.03, for a total value of $278,891.49. Following the completion of the transaction, the chief operating officer now directly owns 844,494 shares of the company’s stock, valued at approximately $10,159,262.82. The trade was a 2.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Patrick Miles sold 12,691 shares of the business’s stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the transaction, the chief executive officer now owns 5,857,603 shares of the company’s stock, valued at $62,324,895.92. This trade represents a 0.22 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 337,321 shares of company stock worth $3,828,060 over the last ninety days. Corporate insiders own 22.80% of the company’s stock.

Institutional Trading of Alphatec

A number of large investors have recently bought and sold shares of the business. R Squared Ltd bought a new stake in shares of Alphatec during the 4th quarter valued at about $29,000. Comerica Bank increased its stake in shares of Alphatec by 66.8% in the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after acquiring an additional 1,248 shares in the last quarter. Nisa Investment Advisors LLC lifted its position in shares of Alphatec by 973.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after acquiring an additional 4,234 shares during the period. Quarry LP boosted its stake in Alphatec by 79.2% during the fourth quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock worth $49,000 after acquiring an additional 2,375 shares in the last quarter. Finally, Newton One Investments LLC acquired a new position in shares of Alphatec during the fourth quarter valued at about $50,000. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Barclays raised their price target on Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a report on Wednesday, January 22nd. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Tuesday, January 14th. Piper Sandler raised their price target on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. StockNews.com upgraded Alphatec from a “sell” rating to a “hold” rating in a report on Friday, February 28th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Alphatec in a research report on Thursday, February 27th. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $17.67.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.